Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

T134 peptide

Known as: T134 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oligopeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Formulation and Evaluation of Mouth Disintegrating Tablets of Atenolol and Atorvastatin
In this study, mouth-disintegrating tablets of atenolol and atorvastatin combination were formulated using superdisintegrants to… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Highly Cited
2005
Highly Cited
2005
Akt Activation, but not Extracellular Signal–Regulated Kinase Activation, Is Required for SDF-1α/CXCR4–Mediated Migration of Epitheloid Carcinoma Cells
Emerging evidence shows that the stromal cell–derived factor 1 (SDF-1)/CXCR4 interaction regulates multiple cell signaling… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2001
Highly Cited
2001
Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
The chemokine receptors CXCR4 and CCR5 are used as co-receptors by the T cell-tropic (X4) and macrophage-tropic (R5) HIV-1… Expand
2001
2001
Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134.
The chemokine receptors CXCR4 and CCR5 are considered to be potential targets for the inhibition of HIV-1 replication. We have… Expand
Highly Cited
2000
Highly Cited
2000
Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.
A polyphemusin peptide analogue, T22 ([Tyr(5,12), Lys7]-polyphemusin II), and its shortened potent analogues, T134 (des-[Cys(8,13… Expand
Review
2000
Review
2000
Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection
  • E. De Clercq
  • Medicinal research reviews
  • 2000
    • Corpus ID: 41451102
A large variety of natural products have been described as anti‐HIV agents, and for a portion thereof the target of interaction… Expand
Highly Cited
1999
Highly Cited
1999
T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure
ABSTRACT T22, an analog of polyphemusin II (18 amino acid residues), was found to block T-tropic human immunodeficiency virus… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
1999
1999
Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
T22 ([Tyr5,12, Lys7]-polyphemusin II) is a strong anti-HIV compound. Six analogs of T22 and two natural forms were synthesized… Expand
Highly Cited
1998
Highly Cited
1998
A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.
T22 ([Tyr5,12, Lys7]-polyphemusin II) is an 18-residue peptide amide, which has strong anti-HIV activity. T22 inhibits the T cell… Expand
Highly Cited
1992
Highly Cited
1992
Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes
Thymosin beta 4 (T beta 4), a 5-kD peptide which binds G-actin and inhibits its polymerization (Safer, D., M. Elzinga, and V. T… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE